Calreticulin

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

Retrieved on: 
Thursday, June 1, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
  • “The presentation of longer-term follow-up data from our pivotal studies and real-world evidence reinforce the potential of cell therapy across different blood cancers, lines of treatment and settings,” said Frank Neumann, MD, PhD, Senior Vice President, Global Head of Clinical Development, Kite.
  • Other data include efficacy and safety information, healthcare resource use in patients with AML and MDS, and proof-of-concept of magrolimab on calreticulin in myelofibrosis CD34-positive cells.
  • “Our data at EHA demonstrate the growing breadth and promise of our development program across many different blood cancers,” said Carol O’Hear, MD, Vice President, Clinical Development, Gilead Oncology.

Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

Retrieved on: 
Sunday, December 11, 2022

This research was featured in the Plenary Scientific Session (Abstract #6.

Key Points: 
  • This research was featured in the Plenary Scientific Session (Abstract #6.
  • Session: Hematology Disease Topics & Pathways: Research, Diseases, Therapies, Myeloid Malignancies) at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-13, 2022, in New Orleans and virtually1.
  • CALR mutations are responsible for disease development in approximately 25-35%2,3 of patients with MF and ET two common types of MPNs.
  • INCA033989 binds with high affinity to mutant CALR and inhibits oncogenesis, the process of cells becoming cancerous, in cells expressing this oncoprotein.

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

Retrieved on: 
Wednesday, January 5, 2022

Under this strategic research collaboration, the two companies will work to determine the benefit of combining Actinium's targeted radiotherapy with EpicentRx's RRx-001, which are both clinical stage drug candidates, in acute myeloid leukemia (AML).

Key Points: 
  • Under this strategic research collaboration, the two companies will work to determine the benefit of combining Actinium's targeted radiotherapy with EpicentRx's RRx-001, which are both clinical stage drug candidates, in acute myeloid leukemia (AML).
  • Actinium's targeted radiotherapies have shown the ability to upregulate the cell surface "eat me" signal calreticulin, which can result in anti-tumor immune response.
  • Actinium's clinical pipeline of targeted radiotherapies, referred to as Antibody Radiation-Conjugates (ARCs), includes Iomab-B and Actimab-A.
  • We are excited to begin this collaboration with Actinium, a company with whom we have good chemistry.

Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Retrieved on: 
Tuesday, September 22, 2020

This new panel expands the HemeScreen offering for reference laboratories and physician office laboratories, enabling them to provide improved patient care through faster turnaround time.

Key Points: 
  • This new panel expands the HemeScreen offering for reference laboratories and physician office laboratories, enabling them to provide improved patient care through faster turnaround time.
  • Among the key genes that comprise the molecular testing for AML and are part of Precipios HemeScreen AML Panel are IDH1, IDH2, FLT3 and KIT mutations.
  • However a survey conducted by Precipio found that some of the largest reference laboratories in the US took 7-14 days to deliver results for molecular testing for AML.
  • As part of the HemeScreen product line of assays, HemeScreen AML joins our current HemeScreen MPN panel which includes the important JAK2, MPL and CALR genes.

Juntendo University Research: Mutant Chaperone Molecule Triggers Cancer

Retrieved on: 
Wednesday, June 27, 2018

Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer.

Key Points: 
  • Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer.
  • The findings may lead to the development of novel therapies for certain types of blood cancer.
  • Mutant CALR, in turn, is known to promote the activation of another protein, thrombopoietin receptor, associated with the development of cancers.Now, a team of researchers led by Marito Araki from Juntendo University has understood the mechanism behind the activation of thrombopoietin receptor through mutant CALR.
  • "Homomultimerization of mutant calreticulin is a prerequisite for MPL2 binding and activation", Leukemia (2018), Published online 26 June 2018.